Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult Population Clear all
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

NCT04187144
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
1,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
79
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 4, 2026, 1:53 PM EDT
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
PF-05221304 Monotherapy, PF-06865571 Monotherapy, Placebo, PF-05221304 and PF-06865571 Combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
29
States / cities
Bakersfield, California • Beverly Hills, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 4, 2026, 1:53 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036
View directory record Official record
Conditions
Psoriatic Arthritis, Axial Spondyloarthritis
Interventions
Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Peoria, Arizona • Apple Valley, California • Covina, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 4, 2026, 1:53 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

NCT01011296
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04427429
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Not applicable Interventional

Exploring the Outcomes and Financial Impact of a CBT-I Group Program Provided by Registered Nurses for Adults With Insomnia

NCT02038556
View directory record Official record
Conditions
Insomnia
Interventions
cognitive behaviorial therapy -Insomnia
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00107731
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • Chula Vista, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 4, 2026, 1:53 PM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

NCT04439695
View directory record Official record
Conditions
Influenza
Interventions
Low dose, Intermediate dose, High dose, Placebo
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

NCT00549653
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
GW856553
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Sep 4, 2026, 1:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations

NCT07424365
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Parkinsons Disease (PD), Healthy Adult
Interventions
transcutaneous auricular vagus nerve stimulation, sham stimulation
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
77
States / cities
Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

NCT00612456
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 4, 2026, 1:53 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants

NCT07635095
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Autoinjector, Vial and syringe
Combination Product · Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT05329194
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Not applicable Interventional

Comparison of In-Person Versus Remote Cochlear Implant Candidacy Evaluations

NCT02684175
View directory record Official record
Conditions
Hearing Loss, Hearing Disorders
Interventions
Remote CI Counseling, In-Person CI Counseling
Device · Other
Lead sponsor
Matthew Bush, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

On the Move: Optimizing Participation in Group Exercise

NCT01986647
View directory record Official record
Conditions
Physical Disability
Interventions
On the Move exercise - exercise leader, Standard program - exercise leader, On the Move exercise - staff activity personnel, Standard program - staff activity personnel
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 4, 2026, 1:53 PM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 4, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 4, 2026, 1:53 PM EDT